Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...

Already approved for progressive multiple sclerosis, ocrelizumab in a second phase 3 study demonstrates meaningful clinical ...

Currently, seven CAR T-cell therapies 1 and six T-cell engager therapies have been approved by the FDA. 2 Despite these advancements and their clear benefits, immunotherapy-based treatments carry ...